Long-term treatment with GLP-1 analogs disturbs glucose homeostasis (Abdulreda et al., 2016), and combination therapy of sulfonylurea and DPP4 inhibitors (that elevate cAMP) has been shown to lead to severe hypoglycemia (Yabe and Seino, 2014), an effect that likely depends on Epac (Takahashi et al., 2015). The gene discussed is DPP4; the disease is Hypoglycemia.